RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M.
Published Sep 21, 2026, 10:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SION
Bearish
medium confidence
Mentioned
$SION
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIONBearishMed
01

Why it matters

The disclosed sale provides fresh insight into insider sentiment, which can influence short‑term trading decisions.

02

Market read

First‑report insider sale of a sizable amount; may prompt traders to reassess SION's near‑term outlook.

03

What to watch

Potential upcoming clinical data releases or financing events that could offset sell pressure.

Relevance 7/10Novelty 7/10Timing: after-hours 2026-09-21 filing

Background

Form 4 filings disclose insider transactions; RA Capital Management is a known biotech investor.

Company-level read

Ticker impact

$SIONBearishMedium confidence
Context

RA Capital Management sold ~3.45M shares of Sionna Therapeutics for $21.8M via a Form 4 filing.

Expected impact

Possible short-term downside pressure; watch for further insider activity.

Evidence & confidence

The sale represents a significant dollar amount for a micro‑cap biotech and is disclosed for the first time, indicating material insider activity.

Market effects

May affect sentiment in the biotech sector as insider sales are monitored closely.

Limited to U.S. biotech investors; no broader regional effect.

Low; relevance confined to SION shareholders and biotech niche.

Counterpoint

Insider sell could be routine portfolio rebalancing rather than a negative signal.

Key entities

  • RA Capital Management, L.P.

    Investment manager and director of SION.

  • Sionna Therapeutics, Inc.

    Biotech firm developing therapeutics; ticker SION.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIONLowAI 8/10

Sionna Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary

Sionna Therapeutics reported a wider net loss of $32.42M in Q3 2026, up 59.9% YoY, due to increased R&D and administrative expenses. The company selected SION-451 + SION-2222 for its dual combination program but will not advance SION-719 after a failed trial. It reduced its workforce by 46% and expects its cash runway to extend into 2H 2029.

$SIONMed

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Third Quarter 2026 Financial Results Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 Clinical and nonclinical data presented at 2026 NACFC support advance

$SIONMedAI 8/10

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Sionna Therapeutics (Nasdaq: SION) will present data at the 2026 North American Cystic Fibrosis Conference. The company reported post hoc analyses of the PreciSION CF trial, showing an 8.6 mmol/L sweat chloride reduction with SION-719. Sionna plans to advance SION-451 + SION-2222 into a Phase 2a trial in early 2027. Preclinical data suggests potential benefits for a broad CF population.

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo